Cargando…

Metabolic Changes in Polycystic Kidney Disease as a Potential Target for Systemic Treatment

Autosomal recessive and autosomal dominant polycystic kidney disease (ARPKD, ADPKD) are systemic disorders with pronounced hepatorenal phenotypes. While the main underlying genetic causes of both ARPKD and ADPKD have been well-known for years, the exact molecular mechanisms resulting in the observed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haumann, Sophie, Müller, Roman-Ulrich, Liebau, Max C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503958/ https://www.ncbi.nlm.nih.gov/pubmed/32847032 http://dx.doi.org/10.3390/ijms21176093

Ejemplares similares

Early clinical management of autosomal recessive polycystic kidney disease
por: Liebau, Max Christoph
Publicado: (2021)

Translational research approaches to study pediatric polycystic kidney disease
por: Liebau, Max Christoph, et al.
Publicado: (2021)

Polycystic Kidney Disease Drug Development: A Conference Report
por: Liebau, Max C., et al.
Publicado: (2022)

Recent Progress of the ARegPKD Registry Study on Autosomal Recessive Polycystic Kidney Disease
por: Ebner, Kathrin, et al.
Publicado: (2017)

Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial
por: Janssens, Peter, et al.
Publicado: (2020)

An Emerging Molecular Understanding and Novel Targeted Treatment Approaches in Pediatric Kidney Diseases
por: Liebau, Max Christoph
Publicado: (2014)

Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective
por: De Rechter, Stéphanie, et al.
Publicado: (2018)

Management of autosomal-dominant polycystic kidney disease—state-of-the-art
por: Müller, Roman-Ulrich, et al.
Publicado: (2018)

Systematic review on outcomes used in clinical research on autosomal recessive polycystic kidney disease—are patient-centered outcomes our blind spot?
por: Gimpel, Charlotte, et al.
Publicado: (2021)

Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease
por: Mekahli, Djalila, et al.
Publicado: (2023)

Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
por: Müller, Roman-Ulrich, et al.
Publicado: (2018)

Gastrostomy Tube Insertion in Pediatric Patients With Autosomal Recessive Polycystic Kidney Disease (ARPKD): Current Practice
por: Burgmaier, Kathrin, et al.
Publicado: (2018)

Cyst Fraction as a Biomarker in Autosomal Dominant Polycystic Kidney Disease
por: Karner, Larina A., et al.
Publicado: (2022)

Shift from severe hypotension to salt-dependent hypertension in a child with autosomal recessive polycystic kidney disease after bilateral nephrectomies: a case report
por: Ruzgiene, Dovile, et al.
Publicado: (2023)

Clinicians’ attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease
por: De Rechter, Stéphanie, et al.
Publicado: (2017)

Editorial: Genetic Kidney Diseases of Childhood
por: Schmidts, Miriam, et al.
Publicado: (2018)

Phenotypic Variability in Siblings With Autosomal Recessive Polycystic Kidney Disease
por: Ajiri, Ramona, et al.
Publicado: (2022)

Non-coding RNAs as potential biomarkers and therapeutic targets in polycystic kidney disease
por: Zheng, Qi, et al.
Publicado: (2022)

Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease
por: Weimbs, Thomas, et al.
Publicado: (2018)

Metabolic derangement in polycystic kidney disease mouse models is ameliorated by mitochondrial-targeted antioxidants
por: Daneshgar, Nastaran, et al.
Publicado: (2021)

Occurrence of Portal Hypertension and Its Clinical Course in Patients With Molecularly Confirmed Autosomal Recessive Polycystic Kidney Disease (ARPKD)
por: Wicher, Dorota, et al.
Publicado: (2020)

Ciliopathies - from rare inherited cystic kidney diseases to basic cellular function
por: Habbig, Sandra, et al.
Publicado: (2015)

Clinical Characteristics and Courses of Patients With Autosomal Recessive Polycystic Kidney Disease-Mimicking Phenocopies
por: Halawi, Abdul A., et al.
Publicado: (2023)

Metabolism-based approaches for autosomal dominant polycystic kidney disease
por: Bakaj, Ivona, et al.
Publicado: (2023)

Change in kidney volume after kidney transplantation in patients with autosomal polycystic kidney disease
por: Veroux, Massimiliano, et al.
Publicado: (2018)

Clinical courses and complications of young adults with Autosomal Recessive Polycystic Kidney Disease (ARPKD)
por: Burgmaier, Kathrin, et al.
Publicado: (2019)

Molecular genetic analysis of polycystic kidney disease 1 and polycystic kidney disease 2 mutations in pedigrees with autosomal dominant polycystic kidney disease
por: Bitarafan, Fatemeh, et al.
Publicado: (2019)

An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
por: Müller, Roman-Ulrich, et al.
Publicado: (2021)

Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment
por: Halvorson, Christian R, et al.
Publicado: (2010)

Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease
por: Klawitter, Jelena, et al.
Publicado: (2013)

Beyond polycystic kidney disease
por: Santos, Susana Franco, et al.
Publicado: (2017)

AMPK and Polycystic Kidney Disease Drug Development: An Interesting Off-Target Target
por: Caplan, Michael J.
Publicado: (2022)

Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling
por: Woodhead, J. L., et al.
Publicado: (2020)

Autosomal Dominant Polycystic Kidney Disease with Emphysematous Polycystic Renal Infection That Required Surgical Treatment
por: Watanabe, Kentaro, et al.
Publicado: (2018)

The wind of change in the management of autosomal dominant polycystic kidney disease in childhood
por: Gimpel, Charlotte, et al.
Publicado: (2021)

Polycystic kidney diseases: From molecular discoveries to targeted therapeutic strategies
por: Ibraghimov-Beskrovnaya, O., et al.
Publicado: (2007)

Therapeutic Potential for CFTR Correctors in Autosomal Recessive Polycystic Kidney Disease
por: Yanda, Murali K., et al.
Publicado: (2021)

Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease
por: Sweeney, William E, et al.
Publicado: (2017)

International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people
por: Gimpel, Charlotte, et al.
Publicado: (2019)

Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease
por: Baliga, Madhurima M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ut43if8ldkpve7vv5hqp20ajcl